28130086|t|The opioid antagonist, β-funaltrexamine, inhibits lipopolysaccharide -induced neuroinflammation and reduces sickness behavior in mice
28130086|a|Brain pathologies such as neurodegenerative diseases, infection, traumatic brain injury, and mood disorders produce enormous personal and economic burdens. It is well established that neuroinflammation plays an important role in the etiology and/or manifestation of such disorders. Previously, we discovered that beta-funaltrexamine (β-FNA) inhibits inflammatory signaling in human astrocytes in vitro, resulting in reduced expression of proinflammatory cytokines / chemokines. The present study examines the effects of peripherally administered β-FNA on lipopolysaccharide (LPS)-induced neuroinflammation and sickness behavior in vivo. Adult male C57BL/6J mice were administered β-FNA and were then immediately administered bacterial lipopolysaccharide (LPS). At 24h post-injections, sickness behavior was assessed in an open-field test. Following behavioral analysis plasma and brains were collected. Levels of interleukin-6 (IL-6), interferon-γ inducible protein-10 (CXCL10), and monocyte chemoattractant protein-1 (CCL2) were determined by enzyme-linked immunosorbant assay (ELISA). At 24h post- LPS injection, IL-6, CCL2 and CXCL10 were increased in the plasma, whereas, only CCL2 and CXCL10 were elevated in the brain. β-FNA significantly inhibited LPS -induced CXCL10 and CCL2 expression in brain, but minimally or not at all in the plasma. LPS -induced sickness behavior, as indicated by a reduction in distance moved, was prevented by β-FNA. Overall, CXCL10 expression in the brain was most positively and significantly correlated with sickness behavior; whereas, anxiety -like behavior was most positively and significantly correlated with IL-6 and CCL2 levels in the plasma and levels of CXCL10 and CCL2 in the brain. The reduction in sickness behavior may be in part due to decreased chemokine expression in the brain; further examination of the anti-inflammatory and neuroprotective effects of β-FNA is warranted.
28130086	4	21	opioid antagonist	T103	UMLS:C0027410
28130086	23	39	β-funaltrexamine	T103	UMLS:C0053433
28130086	50	68	lipopolysaccharide	T103	UMLS:C0023810
28130086	129	133	mice	T204	UMLS:C1521751
28130086	134	151	Brain pathologies	T038	UMLS:C0006119
28130086	160	186	neurodegenerative diseases	T038	UMLS:C0524851
28130086	188	197	infection	T038	UMLS:C3714514
28130086	199	221	traumatic brain injury	T037	UMLS:C0876926
28130086	227	241	mood disorders	T038	UMLS:C0525045
28130086	405	414	disorders	T038	UMLS:C0012634
28130086	447	466	beta-funaltrexamine	T103	UMLS:C0053433
28130086	468	473	β-FNA	T103	UMLS:C0053433
28130086	497	506	signaling	T038	UMLS:C0037080
28130086	510	515	human	T204	UMLS:C0086418
28130086	516	526	astrocytes	T017	UMLS:C0004112
28130086	558	568	expression	T038	UMLS:C1171362
28130086	588	597	cytokines	T038	UMLS:C0010813
28130086	600	610	chemokines	T103	UMLS:C0282554
28130086	654	666	peripherally	T082	UMLS:C0205100
28130086	667	679	administered	T058	UMLS:C1533734
28130086	680	685	β-FNA	T103	UMLS:C0053433
28130086	689	707	lipopolysaccharide	T103	UMLS:C0023810
28130086	709	712	LPS	T103	UMLS:C0023810
28130086	782	795	C57BL/6J mice	T204	UMLS:C1521751
28130086	814	819	β-FNA	T103	UMLS:C0053433
28130086	846	858	administered	T058	UMLS:C1533734
28130086	869	887	lipopolysaccharide	T103	UMLS:C0023810
28130086	889	892	LPS	T103	UMLS:C0023810
28130086	983	1002	behavioral analysis	T058	UMLS:C1160858
28130086	1003	1009	plasma	T031	UMLS:C0032105
28130086	1014	1020	brains	T017	UMLS:C0006104
28130086	1047	1060	interleukin-6	T103	UMLS:C0021760
28130086	1062	1066	IL-6	T103	UMLS:C0021760
28130086	1069	1102	interferon-γ inducible protein-10	T103	UMLS:C1313708
28130086	1104	1110	CXCL10	T103	UMLS:C1313708
28130086	1117	1151	monocyte chemoattractant protein-1	T103	UMLS:C1452296
28130086	1153	1157	CCL2	T103	UMLS:C1452296
28130086	1178	1211	enzyme-linked immunosorbant assay	T058	UMLS:C0014441
28130086	1213	1218	ELISA	T058	UMLS:C0014441
28130086	1234	1237	LPS	T103	UMLS:C0023810
28130086	1249	1253	IL-6	T103	UMLS:C0021760
28130086	1255	1259	CCL2	T103	UMLS:C1452296
28130086	1264	1270	CXCL10	T103	UMLS:C1313708
28130086	1293	1299	plasma	T031	UMLS:C0032105
28130086	1315	1319	CCL2	T103	UMLS:C1452296
28130086	1324	1330	CXCL10	T103	UMLS:C1313708
28130086	1352	1357	brain	T017	UMLS:C0006104
28130086	1359	1364	β-FNA	T103	UMLS:C0053433
28130086	1389	1392	LPS	T103	UMLS:C0023810
28130086	1402	1408	CXCL10	T103	UMLS:C1313708
28130086	1413	1417	CCL2	T103	UMLS:C1452296
28130086	1418	1428	expression	T038	UMLS:C1171362
28130086	1432	1437	brain	T017	UMLS:C0006104
28130086	1474	1480	plasma	T031	UMLS:C0032105
28130086	1482	1485	LPS	T103	UMLS:C0023810
28130086	1554	1559	moved	T038	UMLS:C0560560
28130086	1578	1583	β-FNA	T103	UMLS:C0053433
28130086	1594	1600	CXCL10	T103	UMLS:C1313708
28130086	1601	1611	expression	T038	UMLS:C1171362
28130086	1619	1624	brain	T017	UMLS:C0006104
28130086	1707	1714	anxiety	T033	UMLS:C0003467
28130086	1784	1788	IL-6	T103	UMLS:C0021760
28130086	1793	1797	CCL2	T103	UMLS:C1452296
28130086	1812	1818	plasma	T031	UMLS:C0032105
28130086	1833	1839	CXCL10	T103	UMLS:C1313708
28130086	1844	1848	CCL2	T103	UMLS:C1452296
28130086	1856	1861	brain	T017	UMLS:C0006104
28130086	1930	1939	chemokine	T103	UMLS:C0282554
28130086	1940	1950	expression	T038	UMLS:C1171362
28130086	1958	1963	brain	T017	UMLS:C0006104
28130086	2041	2046	β-FNA	T103	UMLS:C0053433